Stay updated with breaking news from Shridar ganesan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice. ....
Andrew Evens, DO, MBA, MSc, highlights key points presented during the 2023 Rutgers Cancer Institute of New Jersey’s Annual Oncology Clinical Practice and Research Summit, the clinical implications of these presentations, and lymphoma treatment innovations that Rutgers Cancer Institute is providing to patients throughout New Jersey. ....
In patients with microsatellite instable colorectal cancer harboring druggable kinase fusions, combination therapy targeting specific fusions along with immune checkpoint blockade may improve long-term outcomes, a genomic analysis suggests. ....
Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors. ....